Invasive Aspergillosis (IA) is a severe fungal infection caused by the filamentous fungus Aspergillus. It primarily affects immunocompromised individuals, such as those with hematological malignancies, solid organ transplant recipients, or prolonged neutropenia. Antifungal therapy plays a crucial role in the management of invasive aspergillosis, aiming to control the infection, improve patient outcomes and reduce mortality. This article provides an update on the latest treatment strategies for invasive aspergillosis, highlighting recent advancements and emerging therapeutic options. Invasive aspergillosis typically affects individuals with compromised immune systems, such as those undergoing chemotherapy, organ transplant recipients, or individuals with HIV/AIDS. It can also occur in individuals with certain lung conditions like Chronic Obstructive Pulmonary Disease (COPD) or asthma.
HTML PDFShare this article
Clinical Infectious Diseases: Open Access received 49 citations as per Google Scholar report
